🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults

RecruitingNAAges 18 Years - 80 YearsAllCenter for Health Sciences, Serbia
NCT07317830 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This randomized controlled superiority pilot trial will evaluate the efficacy of two vitamin D3 formulations administered over eight weeks in adults with subclinical or clinical vitamin D deficiency. The study will compare changes in serum 25-hydroxyvitamin D concentrations between formulations, as well as the proportion of participants who will achieve vitamin D sufficiency. Both formulations are expected to improve vitamin D status, with the hypothesis that one formulation will demonstrate superior bioavailability, resulting in greater and faster increases in circulating 25-hydroxyvitamin D. The findings will provide preliminary evidence to inform formulation selection and dosing strategies for correcting vitamin D deficiency and will support the design of larger, confirmatory trials.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years and over * Serum 25(OH)D \< 75 nmol/L * BMI 18.5 - 29.9 kg/m2 * Free of clinically significant acute disorders and severe chronic diseases * No planned travel to high-UV destinations or tanning bed use during the trial * Willing to avoid non-study vitamin D supplements * Able to give written informed consent and comply with study visits * Submitted informed consent Exclusion Criteria: * Pregnancy of breast feeding * Underweight or obesity * History of any dietary supplement use within 8 weeks before screening * Medications that materially alter vitamin D metabolism or calcium balance * Subjects with a history of medicine or alcohol abuse * Abnormal values for lab clinical chemistry (\> 2 SD) * Unwillingness to return for follow-up analysis * Participation in other clinical trials within 60 days prior to screening
💊

What it tests

  • Experimental 1 (powdered supplement)
  • Experimental 2 (oily supplement)
📍

Where

1 site
Center for Health Sciences
Belgrade, Serbia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy